Subscribe
shutterstock_1643947495_andrii_vodolazhskyi
Andrii Vodolazhskyi / Shutterstock.com
17 May 2021Big PharmaAlex Baldwin

AIPPI weighs in on COVID waiver

The International Association for the Protection of Intellectual Property (AIPPI) has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Is big pharma’s antidote to the COVID-19 waiver a viable alternative?
29 July 2021   In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.
Big Pharma
France backs COVID-19 vaccine IP waiver
14 June 2021   French President Emmanuel Macron has committed to backing the proposal to waive IP rights for COVID-19 vaccines ahead of the G7 Summit taking place in England this weekend.
article
(WATCH) Lisa Ferri of Mayer Brown on the COVID-19 waiver
10 June 2021   Talks over a COVID-19 vaccine waiver ended this week at the World Trade Organization in Geneva, with an agreement to work towards a text-based response to the plan.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Big Pharma
Is big pharma’s antidote to the COVID-19 waiver a viable alternative?
29 July 2021   In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.
Big Pharma
France backs COVID-19 vaccine IP waiver
14 June 2021   French President Emmanuel Macron has committed to backing the proposal to waive IP rights for COVID-19 vaccines ahead of the G7 Summit taking place in England this weekend.
article
(WATCH) Lisa Ferri of Mayer Brown on the COVID-19 waiver
10 June 2021   Talks over a COVID-19 vaccine waiver ended this week at the World Trade Organization in Geneva, with an agreement to work towards a text-based response to the plan.

More on this story

Big Pharma
Is big pharma’s antidote to the COVID-19 waiver a viable alternative?
29 July 2021   In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.
Big Pharma
France backs COVID-19 vaccine IP waiver
14 June 2021   French President Emmanuel Macron has committed to backing the proposal to waive IP rights for COVID-19 vaccines ahead of the G7 Summit taking place in England this weekend.
article
(WATCH) Lisa Ferri of Mayer Brown on the COVID-19 waiver
10 June 2021   Talks over a COVID-19 vaccine waiver ended this week at the World Trade Organization in Geneva, with an agreement to work towards a text-based response to the plan.

More features

GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia